Clinical Trials Logo

Hemo-dialysis Therapy clinical trials

View clinical trials related to Hemo-dialysis Therapy.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT01234571 Not yet recruiting - Clinical trials for Pulmonary Hypertension

Impact of Hemo-dialysis Therapy on Blood Levels of Treprostenil in End Stage Renal Disease Patients With Pulmonary Hypertension

Start date: November 2010
Phase: N/A
Study type: Observational

Remodulin (Treprostenil sodium) is synthetic prostacyclin analog available as a solution for administration in the intravenous route. It is approved for treatment of class I - pulmonary hypertension functional capacity stage III-IV. A key factor for the success of pulmonary hypertension therapy is maintaining near constant blood level of a given medications along the day. A sudden decrease in the blood levels might lead to rebound phenomenon; abrupt increase in the pulmonary artery pressure which might lead to acute right ventricular failure and even to sudden death. As some PHT patients suffer are on hemo-dialysis therapy due to end-stage renal disease there is a need to document the variation of the blood level along the dialysis cycle.